TL
Telix Pharmaceuticals Limited
TLX.AX · ASX
$16.50 +1.48% (+$0.24)
1M +10.46%
Market Cap $5.51B
P/E Ratio -
Div. Yield -
ROE 1.74%
Bulios Fair Price
$22.8
38.2% upside
Trenutna cena
$16.5
Podcenjeno Poštena vrednost Precenjeno
Po podatkih Bulios Fair Price je delnica TLX.AX trenutno podcenjena glede na svojo tržno ceno. Kako deluje?
Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?
Piotroski F-Score Moderate
4/9Valuation
9 /100
Expensive EV/EBITDA 99.15x
P/S 4.42x
P/B 8.84x
Growth
100 /100
Growing Rev. growth 98.20%
Book val. growth 98.20%
EPS growth N/A
Profitability
23 /100
Weak Gross margin 53.11%
Net margin 0.89%
Op. margin 2.21%
Quality
13 /100
Poor ROIC 2.56%
ROE 1.74%
ROA 0.62%
Debt
24 /100
High Debt/Equity 1.26x
Current ratio 1.43x
Int. coverage 0.48x
Stability
26 /100
Unstable Beta 0.60x
Rev. volatility 90.31%
EPS volatility 463.92%
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o TLX.AX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Christian Behrenbruch
Employees
1,152
Headquarters
North Melbourne
Prihajajoči dogodki
19 FEB.
Earnings
Upcoming earnings report